Takafumi Iwatsubo

Which concentration of the inhibitor should be used to predict in vivo drug interactions from in vitro data?

Kiyomi Ito, Kōji Chiba, Masato Horikawa et al. · AAPS PharmSci · 2002 · 86 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

<i>In Vitro</i>/<i>in Vivo</i> scaling of alprazolam metabolism by CYP3A4 and CYP3A5 in humans

Noriko Hirota, Kiyomi Ito, Takafumi Iwatsubo et al. · Biopharmaceutics & Drug Disposition · 2001 · 76 citations

Medicine, Pharmacokinetics, Pharmacology +17

Simultaneous Absolute Protein Quantification of Carboxylesterases 1 and 2 in Human Liver Tissue Fractions using Liquid Chromatography-Tandem Mass Spectrometry

Yuichiro Sato, Aiji Miyashita, Takafumi Iwatsubo et al. · Drug Metabolism and Disposition · 2012 · 72 citations

Life Sciences, Biochemistry, Molecular Biology +17

Prediction of Species Differences (Rats, Dogs, Humans) in the In Vivo Metabolic Clearance of YM796 by the Liver from In Vitro Data

Takafumi Iwatsubo, Hiroshi Suzuki, Yuichi Sugiyama · Journal of Pharmacology and Experimental Therapeutics · 1997 · 68 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

Absorption, Metabolism and Excretion of [14C]Mirabegron (YM178), a Potent and Selective β3-Adrenoceptor Agonist, after Oral Administration to Healthy Male Volunteers

Shin Takusagawa, Jan Jaap van Lier, Katsuhiro Suzuki et al. · Drug Metabolism and Disposition · 2012 · 62 citations

Medicine, Pharmacokinetics, Pharmacology +11